These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 21305156)

  • 21. The use of a binary chelate formulation: Could gadolinium based linear contrast agents be rescued by the addition of zinc selective chelates?
    Gibby W; Parish W; Merrill RM; Fernandez D; Anderson CR; Merchel E; Parr R
    Magn Reson Imaging; 2019 May; 58():76-81. PubMed ID: 30639754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Automated colorimetric gadolinium assay for verification of clearance and estimation of glomerular filtration rate.
    Magnotti RA; Connell JL; Marietta PM
    Clin Chim Acta; 2009 Jan; 399(1-2):59-63. PubMed ID: 18834869
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand.
    Sieber MA; Lengsfeld P; Walter J; Schirmer H; Frenzel T; Siegmund F; Weinmann HJ; Pietsch H
    J Magn Reson Imaging; 2008 May; 27(5):955-62. PubMed ID: 18425843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distribution and clearance of retained gadolinium in the brain: differences between linear and macrocyclic gadolinium based contrast agents in a mouse model.
    Kartamihardja AA; Nakajima T; Kameo S; Koyama H; Tsushima Y
    Br J Radiol; 2016 Oct; 89(1066):20160509. PubMed ID: 27459250
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of human serum albumin on longitudinal and transverse relaxation rates (r1 and r2) of magnetic resonance contrast agents.
    Giesel FL; von Tengg-Kobligk H; Wilkinson ID; Siegler P; von der Lieth CW; Frank M; Lodemann KP; Essig M
    Invest Radiol; 2006 Mar; 41(3):222-8. PubMed ID: 16481904
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gd accumulation in tissues of healthy mice upon repeated administrations of Gadodiamide and Gadoteridol.
    Di Gregorio E; Iani R; Ferrauto G; Nuzzi R; Aime S; Gianolio E
    J Trace Elem Med Biol; 2018 Jul; 48():239-245. PubMed ID: 29773187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An intravascular MRI contrast agent based on Gd(DO3A-Lys) for tumor angiography.
    Yang CT; Chandrasekharan P; He T; Poh Z; Raju A; Chuang KH; Robins EG
    Biomaterials; 2014 Jan; 35(1):327-36. PubMed ID: 24138829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative in vivo dissociation of gadolinium chelates in renally impaired rats: a relaxometry study.
    Fretellier N; Idée JM; Dencausse A; Karroum O; Guerret S; Poveda N; Jestin G; Factor C; Raynal I; Zamia P; Port M; Corot C
    Invest Radiol; 2011 May; 46(5):292-300. PubMed ID: 21263333
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does Age Interfere With Gadolinium Toxicity and Presence in Brain and Bone Tissues?: A Comparative Gadoterate Versus Gadodiamide Study in Juvenile and Adult Rats.
    Fretellier N; Granottier A; Rasschaert M; Grindel AL; Baudimont F; Robert P; Idée JM; Corot C
    Invest Radiol; 2019 Feb; 54(2):61-71. PubMed ID: 30394964
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review.
    Idée JM; Port M; Raynal I; Schaefer M; Le Greneur S; Corot C
    Fundam Clin Pharmacol; 2006 Dec; 20(6):563-76. PubMed ID: 17109649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dissociation kinetics of open-chain and macrocyclic gadolinium(III)-aminopolycarboxylate complexes related to magnetic resonance imaging: catalytic effect of endogenous ligands.
    Baranyai Z; Pálinkás Z; Uggeri F; Maiocchi A; Aime S; Brücher E
    Chemistry; 2012 Dec; 18(51):16426-35. PubMed ID: 23139193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distribution profile of gadolinium in gadolinium chelate-treated renally-impaired rats: role of pharmaceutical formulation.
    Fretellier N; Salhi M; Schroeder J; Siegmund H; Chevalier T; Bruneval P; Jestin-Mayer G; Delaloge F; Factor C; Mayer JF; Fabicki JM; Robic C; Bonnemain B; Idée JM; Corot C
    Eur J Pharm Sci; 2015 May; 72():46-56. PubMed ID: 25736527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis.
    High WA; Ayers RA; Chandler J; Zito G; Cowper SE
    J Am Acad Dermatol; 2007 Jan; 56(1):21-6. PubMed ID: 17097388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gadolinium tissue deposition in the periodontal ligament of mice with reduced renal function exposed to Gd-based contrast agents.
    Delfino R; Biasotto M; Candido R; Altissimo M; Stebel M; Salomè M; van Elteren JT; Vogel Mikuš K; Zennaro C; Šala M; Addobbati R; Tromba G; Pascolo L
    Toxicol Lett; 2019 Feb; 301():157-167. PubMed ID: 30476537
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting.
    Broome DR
    Eur J Radiol; 2008 May; 66(2):230-4. PubMed ID: 18372138
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study.
    Kallen AJ; Jhung MA; Cheng S; Hess T; Turabelidze G; Abramova L; Arduino M; Guarner J; Pollack B; Saab G; Patel PR
    Am J Kidney Dis; 2008 Jun; 51(6):966-75. PubMed ID: 18501784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla.
    Pintaske J; Martirosian P; Graf H; Erb G; Lodemann KP; Claussen CD; Schick F
    Invest Radiol; 2006 Mar; 41(3):213-21. PubMed ID: 16481903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human comparative study of zinc and copper excretion via urine after administration of magnetic resonance imaging contrast agents.
    Kimura J; Ishiguchi T; Matsuda J; Ohno R; Nakamura A; Kamei S; Ohno K; Kawamura T; Murata K
    Radiat Med; 2005 Aug; 23(5):322-6. PubMed ID: 16342903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differences in gadolinium retention after repeated injections of macrocyclic MR contrast agents to rats.
    Bussi S; Coppo A; Botteron C; Fraimbault V; Fanizzi A; De Laurentiis E; Colombo Serra S; Kirchin MA; Tedoldi F; Maisano F
    J Magn Reson Imaging; 2018 Mar; 47(3):746-752. PubMed ID: 28730643
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of lanthanoids as X-ray contrast agents.
    Pietsch H; Jost G; Frenzel T; Raschke M; Walter J; Schirmer H; Hütter J; Sieber MA
    Eur J Radiol; 2011 Nov; 80(2):349-56. PubMed ID: 20006455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.